Inactive

The U.S. Food and Drug Administration (FDA) is issuing this sources sought notice as a means of conducting market research, pursuant to FAR Part 10, to identify potential sources from the marketplace ... The U.S. Food and Drug Administration (FDA) is issuing this sources sought notice as a means of conducting market research, pursuant to FAR Part 10, to identify potential sources from the marketplace capable of providing a brand-name only Illumina NextSeq 2000 Sequencing System. The anticipated acquisition is for a complete system to include, but not limited to a touchscreen monitor, integrated computer, control software, and secondary analysis pipelines. The anticipated acquisition also includes a trade-in of an existing instrument: one (1) Illumina NextSeq 500. The following shall also be included: training, warranty, and a preventative maintenance agreement. This is a SOURCES SOUGHT NOTICE ONLY (i.e., not a Request for Quotes or Proposals). This notice does not commit the Government to award a contract action now or in the future. The purpose of this notice is to identify sources with the capabilities to provide all products and services required as outlined in the attached draft Performance Work Statement (PWS). If you believe your company is capable of providing all products/services required, please respond with a capability statement along with responses to the following no later than the response date indicated within this notice: Can your company provide all products and services as outlined within the draft PWS? Can your company process the Illumina trade-in for a purchase discount/credit and as required within the draft PWS? Please provide your company name and SAM Unique Entity ID. Be advised that no reimbursement will be made for any costs associated with providing information in response to this notice or any follow-up information requests. Response Date: 01/19/2024 at 4:30 p.m. ET. Please email responses with subject line “RFI Responses for Illumina NextSeq 2000” to Contract Specialist Benjamin Dorgan at benjamin.dorgan@fda.hhs.gov. No phone calls will be accepted.